Format
Sort by

Send to

Choose Destination

Search results

Items: 1 to 20 of 28

1.

Multidrug-resistant tuberculosis treatment failure detection depends on monitoring interval and microbiological method.

Mitnick CD, White RA, Lu C, Rodriguez CA, Bayona J, Becerra MC, Burgos M, Centis R, Cohen T, Cox H, D'Ambrosio L, Danilovitz M, Falzon D, Gelmanova IY, Gler MT, Grinsdale JA, Holtz TH, Keshavjee S, Leimane V, Menzies D, Migliori GB, Milstein MB, Mishustin SP, Pagano M, Quelapio MI, Shean K, Shin SS, Tolman AW, van der Walt ML, Van Deun A, Viiklepp P;  on behalf of the Collaborative Group for Analysis of Bacteriology Data in MDR-TB Treatment..

Eur Respir J. 2016 Oct;48(4):1160-1170. doi: 10.1183/13993003.00462-2016.

2.

Propensity Score-Based Approaches to Confounding by Indication in Individual Patient Data Meta-Analysis: Non-Standardized Treatment for Multidrug Resistant Tuberculosis.

Fox GJ, Benedetti A, Mitnick CD, Pai M, Menzies D; Collaborative Group for Meta-Analysis of Individual Patient Data in MDR-TB..

PLoS One. 2016 Mar 29;11(3):e0151724. doi: 10.1371/journal.pone.0151724.

3.

Surgery as an Adjunctive Treatment for Multidrug-Resistant Tuberculosis: An Individual Patient Data Metaanalysis.

Fox GJ, Mitnick CD, Benedetti A, Chan ED, Becerra M, Chiang CY, Keshavjee S, Koh WJ, Shiraishi Y, Viiklepp P, Yim JJ, Pasvol G, Robert J, Shim TS, Shin SS, Menzies D; Collaborative Group for Meta-Analysis of Individual Patient Data in MDR-TB..

Clin Infect Dis. 2016 Apr 1;62(7):887-95. doi: 10.1093/cid/ciw002.

PMID:
26757804
4.

Treatment outcomes of patients with multidrug-resistant and extensively drug-resistant tuberculosis according to drug susceptibility testing to first- and second-line drugs: an individual patient data meta-analysis.

Bastos ML, Hussain H, Weyer K, Garcia-Garcia L, Leimane V, Leung CC, Narita M, Penã JM, Ponce-de-Leon A, Seung KJ, Shean K, Sifuentes-Osornio J, Van der Walt M, Van der Werf TS, Yew WW, Menzies D; Collaborative Group for Meta-analysis of Individual Patient Data in MDR-TB..

Clin Infect Dis. 2014 Nov 15;59(10):1364-74. doi: 10.1093/cid/ciu619.

5.

Genotypic characteristics of Mycobacterium tuberculosis isolated from household contacts of tuberculosis patients in the Philippines.

Sia IG, Buckwalter SP, Doerr KA, Lugos S, Kramer R, Orillaza-Chi R, Quelapio MI, Tupasi TE, Wengenack NL.

BMC Infect Dis. 2013 Dec 5;13:571. doi: 10.1186/1471-2334-13-571.

6.

Patterns of treatment interruption among patients with multidrug-resistant TB (MDR TB) and association with interim and final treatment outcomes.

Podewils LJ, Gler MT, Quelapio MI, Chen MP.

PLoS One. 2013 Jul 29;8(7):e70064. doi: 10.1371/journal.pone.0070064.

7.

Predictors of sputum culture conversion among patients treated for multidrug-resistant tuberculosis.

Kurbatova EV, Gammino VM, Bayona J, Becerra MC, Danilovitz M, Falzon D, Gelmanova I, Keshavjee S, Leimane V, Mitnick CD, Quelapio MI, Riekstina V, Taylor A, Viiklepp P, Zignol M, Cegielski JP.

Int J Tuberc Lung Dis. 2012 Oct;16(10):1335-43. doi: 10.5588/ijtld.11.0811.

PMID:
23107633
8.

Resistance to fluoroquinolones and second-line injectable drugs: impact on multidrug-resistant TB outcomes.

Falzon D, Gandhi N, Migliori GB, Sotgiu G, Cox HS, Holtz TH, Hollm-Delgado MG, Keshavjee S, DeRiemer K, Centis R, D'Ambrosio L, Lange CG, Bauer M, Menzies D; Collaborative Group for Meta-Analysis of Individual Patient Data in MDR-TB..

Eur Respir J. 2013 Jul;42(1):156-68. doi: 10.1183/09031936.00134712.

9.

Drug resistance beyond extensively drug-resistant tuberculosis: individual patient data meta-analysis.

Migliori GB, Sotgiu G, Gandhi NR, Falzon D, DeRiemer K, Centis R, Hollm-Delgado MG, Palmero D, Pérez-Guzmán C, Vargas MH, D'Ambrosio L, Spanevello A, Bauer M, Chan ED, Schaaf HS, Keshavjee S, Holtz TH, Menzies D; Collaborative Group for Meta-Analysis of Individual Patient Data in MDR-TB..

Eur Respir J. 2013 Jul;42(1):169-79. doi: 10.1183/09031936.00136312.

10.

Multidrug resistant pulmonary tuberculosis treatment regimens and patient outcomes: an individual patient data meta-analysis of 9,153 patients.

Ahuja SD, Ashkin D, Avendano M, Banerjee R, Bauer M, Bayona JN, Becerra MC, Benedetti A, Burgos M, Centis R, Chan ED, Chiang CY, Cox H, D'Ambrosio L, DeRiemer K, Dung NH, Enarson D, Falzon D, Flanagan K, Flood J, Garcia-Garcia ML, Gandhi N, Granich RM, Hollm-Delgado MG, Holtz TH, Iseman MD, Jarlsberg LG, Keshavjee S, Kim HR, Koh WJ, Lancaster J, Lange C, de Lange WC, Leimane V, Leung CC, Li J, Menzies D, Migliori GB, Mishustin SP, Mitnick CD, Narita M, O'Riordan P, Pai M, Palmero D, Park SK, Pasvol G, Peña J, Pérez-Guzmán C, Quelapio MI, Ponce-de-Leon A, Riekstina V, Robert J, Royce S, Schaaf HS, Seung KJ, Shah L, Shim TS, Shin SS, Shiraishi Y, Sifuentes-Osornio J, Sotgiu G, Strand MJ, Tabarsi P, Tupasi TE, van Altena R, Van der Walt M, Van der Werf TS, Vargas MH, Viiklepp P, Westenhouse J, Yew WW, Yim JJ; Collaborative Group for Meta-Analysis of Individual Patient Data in MDR-TB..

PLoS Med. 2012;9(8):e1001300.

11.

Predictors of poor outcomes among patients treated for multidrug-resistant tuberculosis at DOTS-plus projects.

Kurbatova EV, Taylor A, Gammino VM, Bayona J, Becerra M, Danilovitz M, Falzon D, Gelmanova I, Keshavjee S, Leimane V, Mitnick CD, Quelapio MI, Riekstina V, Viiklepp P, Zignol M, Cegielski JP.

Tuberculosis (Edinb). 2012 Sep;92(5):397-403. doi: 10.1016/j.tube.2012.06.003.

12.

Impact of patient and program factors on default during treatment of multidrug-resistant tuberculosis.

Gler MT, Podewils LJ, Munez N, Galipot M, Quelapio MI, Tupasi TE.

Int J Tuberc Lung Dis. 2012 Jul;16(7):955-60. doi: 10.5588/ijtld.11.0502.

13.

Bacteriologic monitoring of multidrug-resistant tuberculosis patients in five DOTS-Plus pilot projects.

Gammino VM, Taylor AB, Rich ML, Bayona J, Becerra MC, Bonilla C, Gelmanova I, Hollo V, Jaramillo E, Keshavjee S, Leimane V, Mitnick CD, Quelapio MI, Riektsina V, Tupasi TE, Wells CD, Zignol M, Cegielski PJ.

Int J Tuberc Lung Dis. 2011 Oct;15(10):1315-22. doi: 10.5588/ijtld.10.0221.

PMID:
22283887
14.

Frequency and type of microbiological monitoring of multidrug-resistant tuberculosis treatment.

Kurbatova EV, Gammino VM, Bayona J, Becerra M, Danilovitz M, Falzon D, Gelmanova I, Keshavjee S, Leimane V, Mitnick CD, Quelapio MI, Riekstina V, Taylor A, Viiklepp P, Zignol M, Cegielski JP.

Int J Tuberc Lung Dis. 2011 Nov;15(11):1553-5, i. doi: 10.5588/ijtld.11.0101.

PMID:
22008772
15.

WHO guidelines for the programmatic management of drug-resistant tuberculosis: 2011 update.

Falzon D, Jaramillo E, Schünemann HJ, Arentz M, Bauer M, Bayona J, Blanc L, Caminero JA, Daley CL, Duncombe C, Fitzpatrick C, Gebhard A, Getahun H, Henkens M, Holtz TH, Keravec J, Keshavjee S, Khan AJ, Kulier R, Leimane V, Lienhardt C, Lu C, Mariandyshev A, Migliori GB, Mirzayev F, Mitnick CD, Nunn P, Nwagboniwe G, Oxlade O, Palmero D, Pavlinac P, Quelapio MI, Raviglione MC, Rich ML, Royce S, Rüsch-Gerdes S, Salakaia A, Sarin R, Sculier D, Varaine F, Vitoria M, Walson JL, Wares F, Weyer K, White RA, Zignol M.

Eur Respir J. 2011 Sep;38(3):516-28. doi: 10.1183/09031936.00073611.

16.

Clinical symptoms and microbiological outcomes in tuberculosis treatment trials.

Bark CM, Dietze R, Okwera A, Quelapio MI, Thiel BA, Johnson JL.

Tuberculosis (Edinb). 2011 Nov;91(6):601-4. doi: 10.1016/j.tube.2011.05.007.

17.

Multidrug-resistant tuberculosis among previously treated patients in the Philippines.

Gler MT, Macalintal LE, Raymond L, Guilatco R, Quelapio MI, Tupasi TE.

Int J Tuberc Lung Dis. 2011 May;15(5):652-6. doi: 10.5588/ijtld.10.0400.

PMID:
21756517
18.

Responding to the multidrug-resistant tuberculosis crisis: mainstreaming programmatic management to the Philippine National Tuberculosis Programme.

Quelapio MI, Mira NR, Orillaza-Chi RB, Belen V, Muñez N, Belchez R, Egos GE, Evangelista M, Vianzon R, Tupasi TE.

Int J Tuberc Lung Dis. 2010 Jun;14(6):751-7.

PMID:
20487615
19.

Significant decline in the tuberculosis burden in the Philippines ten years after initiating DOTS.

Tupasi TE, Radhakrishna S, Chua JA, Mangubat NV, Guilatco R, Galipot M, Ramos G, Quelapio MI, Beltran G, Legaspi J, Vianzon RG, Lagahid J.

Int J Tuberc Lung Dis. 2009 Oct;13(10):1224-30.

PMID:
19793426
20.

Shortening treatment in adults with noncavitary tuberculosis and 2-month culture conversion.

Johnson JL, Hadad DJ, Dietze R, Maciel EL, Sewali B, Gitta P, Okwera A, Mugerwa RD, Alcaneses MR, Quelapio MI, Tupasi TE, Horter L, Debanne SM, Eisenach KD, Boom WH.

Am J Respir Crit Care Med. 2009 Sep 15;180(6):558-63. doi: 10.1164/rccm.200904-0536OC.

Items per page

Supplemental Content

Loading ...
Support Center